Tony Zook

Tony became CEO of NeoGenomics in April 2025. Prior to becoming CEO, he was a Board member for two years, serving as Chair of the Compensation committee and a member of the Audit and Technology committees. Tony has significant experience as a brand and marketing executive, with a focus on managing the interface between commercial and research and development aspects of an organization. Prior to serving as Chief Executive Officer of Innocoll Biotherapeutics, Tony was Executive Vice President, Commercial Operations of AstraZeneca (AZ), where he held global P&L responsibility for all of AZ’s brands and markets. Under Tony’s leadership, AZ commercialized 10 brands, each in excess of $1 billion in sales. Tony was responsible for MedImmune, AZ’s global biologics business. He also chaired the Commercial Investment Board, which identified and approved critical investments company-wide, including investments in plants, markets, and technology. Earlier in his career at AZ, Tony held various positions, including CEO of North America and VP of Sales, where he helped lead the integrations of Astra US, Astra Merck, and Zeneca. Prior to joining AZ, Tony spent 14 years with Berlex Laboratories in a variety of positions.